Neomangiferin

Neomangiferin is an orally active natural flavonoid. Neomangiferin partially ameliorates non-alcoholic fatty liver disease (NAFLD) by regulating the expression of genes related to free fatty acid uptake and lipid oxidation. Neomangiferin exerts anti-colitis effects by inhibiting Th17/Treg cell differentiation. Neomangiferin exerts anti-aging and lifespan-extending effects by targeting upregulation of bas-1, which in turn activates the autophagy, IIS and MAPK pathways. Neomangiferin has the potential to prevent aseptic loosening of prostheses after total joint arthroplasty due to its significant anti-inflammatory and osteoclastogenesis-inhibiting effects^[1][2][3][4]. In Vitro:Neomangiferin (5, 10, 20 μM; 5 days) suppresses TGFβ/IL-6-induced Th17 cell differentiation in purified splenic CD4⁺ T cells from C57BL/6J mice, reducing IL-17 and RORγt expression^[2].
Neomangiferin (5, 10, 20 μM; 5 days) promotes anti-CD3/anti-CD28-induced Treg cell differentiation in purified splenic T cells from C57BL/6J mice, increasing IL-10 expression^[2]. In Vivo:Neomangiferin (25-50 mg/kg; oral gavage; daily administration; for 13 consecutive weeks) significantly ameliorates high-fat diet-induced non-alcoholic fatty liver disease (NAFLD) in male SD rats via reducing body fat and hepatic lipid accumulation, normalizing serum and hepatic lipid as well as antioxidant parameters, improving glucose tolerance and metabolic rate, and regulating the expression of genes and proteins related to fatty acid uptake and oxidation in the liver^[1].
Neomangiferin (10-20 mg/kg; p.o.; once daily; for 3 consecutive days) ameliorates TNBS-induced colitis in male C57BL/6J mice by inhibiting proinflammatory cytokine production and restoring the Th17/Treg balance; at the dose of 20 mg/kg, it inhibits myeloperoxidase activity by 73.9% and reduces IL-17 levels by 63.6%^[2].
Neomangiferin (20 mg/kg; p.o.; daily; for 3 consecutive weeks) improves spontaneous chronic colitis in male C57BL/6 IL-10 knockout mice by reducing the production of proinflammatory cytokines, inhibiting myeloperoxidase activity by 52.6%, and restoring the Th17/Treg balance^[2].
Neomangiferin (2.5-5 mg/kg, i.p., once every other day for 21 consecutive days) dose-dependently inhibits UHMWPE particle-induced inflammatory calvarial osteolysis in mice^[3].